---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-016619"
form_type: "8-K"
ticker: "TCMD"
cik: "0001027838"
company_name: "TACTILE SYSTEMS TECHNOLOGY INC"
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T04:57:39.094562+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tactile Medical Q3 revenue up 24% to $65.3M; raises FY2022 guidance

## Summary
- Q3 revenue $65.3M (+24% YoY); net loss $2.3M ($0.11/sh) vs loss $3.4M ($0.17) a year ago.
- Non-GAAP net income $1.9M vs non-GAAP loss $1.6M; Adjusted EBITDA $7.2M vs $4.1M.
- Airway clearance revenue $11.0M (incl. AffloVest); lymphedema revenue up 5%.
- Raises FY2022 revenue guidance to $242-245M (16-18% growth) from prior $238-242M.
- Gross margin improved to 71.7% from 70.4%; cash $23.4M, debt $49.8M.

## SEC filing metadata
- accession: 0001558370-22-016619
- form_type: 8-K
- ticker: TCMD
- cik: 0001027838
- company_name: TACTILE SYSTEMS TECHNOLOGY INC
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1027838/000155837022016619/0001558370-22-016619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1027838/000155837022016619/tcmd-20221107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-016619
- JSON: https://secwatch.observer/filing/0001558370-22-016619.json
- Plain text: https://secwatch.observer/filing/0001558370-22-016619.txt

## Key facts
- Earnings Releases
  TACTILE SYSTEMS TECHNOLOGY INC reported the third quarter and nine months ended September 30, 2022 results: revenue $65.3 million, net income $2.3 million, EPS $0.11 per diluted share. Guidance raised.
  - Period: the third quarter and nine months ended September 30, 2022
  - Revenue: $65.3 million
  - Net income: $2.3 million
  - EPS: $0.11 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: today reported financial results for the third quarter and nine months ended September 30, 2022. Third Quarter 2022 Summary: ● Total revenue increased 24% year-over-year to $65.3 million, compared to $52.5 million in third quarter 2021. ● Total revenue in third quarter 2022 included $11.0 million of revenue from sales of airway clearance products, which includes
  evidence_url: https://www.sec.gov/Archives/edgar/data/1027838/000155837022016619/0001558370-22-016619-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.